Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer.
The human multidrug resistance transporter P-glycoprotein (P-gp) prevents the entry of compounds into the brain by an active efflux mechanism at the blood-brain barrier (BBB). Treatment of neurodegenerative diseases, therefore, has become a challenge and the development of new reversible inhibitors of P-gp is pertinent to overcome this problem. We report the design and synthesis of a crosslinked agent based on the Alzheimer's disease treatment galantamine (Gal-2) that inhibits P-gp-mediated efflux from cultured cells. Gal-2 was found to inhibit the efflux of the fluorescent P-gp substrate rhodamine 123 in cancer cells that over-express P-gp with an IC(50) value of approximately 0.6 microM. In addition, Gal-2 was found to inhibit the efflux of therapeutic substrates of P-gp, such as doxorubicin, daunomycin and verapamil with IC(50) values ranging from 0.3 to 1.6 microM. Through competition experiments, it was determined that Gal-2 modulates P-gp mediated efflux by competing for the substrate binding sites. These findings support a potential role of agents, such as Gal-2, as inhibitors of P-gp at the BBB to augment treatment of neurodegenerative diseases.
Namanja
Hilda A
HA
Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907-2084, USA.
Emmert
Dana
D
Pires
Marcos M
MM
Hrycyna
Christine A
CA
Chmielewski
Jean
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000378:metabolism; D003630:Daunorubicin / Q000494:pharmacology; D019281:Dimerization; D004317:Doxorubicin / Q000494:pharmacology; D005702:Galantamine / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D020128:Inhibitory Concentration 50; D014700:Verapamil / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D005702:Galantamine; D004317:Doxorubicin; D014700:Verapamil; D003630:Daunorubicin
Cancer Res. 1993 Oct 1;53(19):4595-602
8402633
J Biol Chem. 1989 Sep 15;264(26):15483-8
2475500
Eur J Biochem. 1997 Nov 15;250(1):130-7
9432000
Ann Pharmacother. 2001 Nov;35(11):1406-13
11724094
Biochemistry. 2006 Sep 26;45(38):11695-702
16981729
Methods Enzymol. 1998;292:318-28
9711564
Mol Pharmacol. 2009 Jan;75(1):92-100
18945821
Pharmacol Biochem Behav. 2006 Nov;85(3):629-36
17134744
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9
9380680
Semin Cancer Biol. 1991 Aug;2(4):213-26
1680493
Epilepsia. 2007;48 Suppl 5:140-9
17910594
Antimicrob Agents Chemother. 2002 Mar;46(3):755-61
11850258
Annu Rev Pharmacol Toxicol. 1999;39:361-98
10331089
J Biol Chem. 1992 Oct 15;267(29):21020-6
1356986
J Biol Chem. 1993 Oct 15;268(29):21493-6
8104940
Xenobiotica. 2008 Jul;38(7-8):802-32
18668431
Annu Rev Biochem. 1993;62:385-427
8102521
J Biol Chem. 2003 Oct 10;278(41):39706-10
12909621
Mol Pharmacol. 2000 Sep;58(3):624-32
10953057
Biochem Pharmacol. 1993 Sep 14;46(6):1096-9
8105783
Proc Natl Acad Sci U S A. 1988 May;85(10):3580-4
3368466
J Psychiatr Res. 2007 Jan-Feb;41(1-2):179-88
16387324
Methods Enzymol. 1998;292:456-73
9711574
Semin Cell Dev Biol. 2001 Jun;12(3):247-56
11428917
Eur J Biochem. 1999 Feb;259(3):841-50
10092872
Life Sci. 2002 May 31;71(2):163-9
12031686
Biol Psychiatry. 2003 Oct 15;54(8):840-6
14550684
Annu Rev Cell Biol. 1992;8:67-113
1282354